Cited by 368Menstrual Health and DisordersMaternal Mental Health During Pregnancy and PostpartumMenopause: Health Impacts and Treatments

Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: A systematic review

Dimmock, Paul W, Wyatt, Katrina M, Jones, Peter W, O'Brien, PM Shaughn·2000·The Lancet

Abstract

Background Selective serotonin-reuptake inhibitors (SSRIs) are increasingly being used as first-line therapy for severe premenstrual syndrome (PMS). We undertook a meta-analysis on the efficacy of SSRIs in this disorder.Methods We searched medical and scientific databases, approached pharmaceutical companies, and reviewed citations of relevant articles to identify 29 studies of the use of SSRIs in PMS. 14 were excluded (no placebo group, preliminary report of included trial, or low quality). 15 randomised placebo-controlled trials were included. Information on study design, participants, drugs used and dosing regimens, outcome measures, side-effects, and sources of funding was extracted. Standardised mean differences between treatment and placebo groups were calculated to obtain an overall estimate of efficacy. The primary outcome measure was a reduction in overall PMS symptoms.Findings The primary analysis included data on 904 women (570 assigned active treatment and 435 assigned placebo, including 101 in crossover trials). The overall standardised mean difference was -1.066 (95% CI -1.381 to -0.750), which corresponds to an odds ratio of 6.91 (3.90 to 12.2) in favour of SSRIs. SSRIs were effective in treating physical and behavioural symptoms. There was no significant difference in symptom reduction between continuous and intermittent dosing or between trials funded by pharmaceutical companies and those independently funded. Withdrawal due to side-effects was 2.5 times more likely in the active-treatment group than in the placebo group.Interpretation SSRIs are an effective first-line therapy for severe PMS. The safety of these drugs has been demonstrated in trials of affective disorder, and the side-effects at low doses are generally acceptable.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(00)02754-9

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

2 of the 47 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Dimmock, P. W., Wyatt, K. M., Jones, P. W., & O'Brien, P. S.
Affiliations
  • University Hospitals of North Midlands NHS Trust (GB)
  • Keele University (GB)
Corresponding author
Dimmock, Paul W
Venue
The Lancet
Publisher
Elsevier BV
Published
2000-09
Volume
356
Issue
9236
Pages
1131-1136
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2119435034
Cited by
368
References
47
Citations by year
2026: 7 · 2025: 3 · 2024: 6 · 2023: 10 · 2022: 11 · 2021: 4 · 2020: 4 · 2019: 7 · 2018: 9 · 2017: 11 · 2016: 16 · 2015: 14 · 2014: 11 · 2013: 13 · 2012: 10
FWCI
5.88
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
selective serotonin reuptake inhibitors, premenstrual syndrome, drug efficacy, pharmaceutical industry funding, adverse drug reactions, first-line therapy
MeSH terms
Female, Humans, Patient Dropouts, Premenstrual Syndrome, Randomized Controlled Trials as Topic, Treatment Outcome, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review